| |
|
Headlines:
|
 |
Back
to index
5-Fluorouracil, doxorubicin, mitomycin (FAM) regimen
Abstract: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination
chemotherapy for advanced gastric cancer.
Sixty-two patients with advanced
measurable gastric cancer were treated with a combination chemotherapy program
of 5-fluorouracil, doxorubicin, and mitomycin (FAM). Forty-two percent of
patients achieved an objective partial response. The median duration of
remission was 9 months and the median survival for responding patients,
12.5 months. The median survival for nonresponding patients was 3.5 months;
all patients were dead by 8 months after initiation of therapy. The median
survival of all 62 patients treated with FAM was
5.5 months. An analysis of possible prognostic
variables including initial performance status, resectability of the primary
gastric tumor, and histologic differentiation of the neoplasm failed to
account for differences in patient response and survival. The FAM regimen
was well tolerated, producing only moderate bone marrow suppression. These
results show that patients with metastatic gastric cancer can be effectively
palliated with FAM chemotherapy. The efficacy of this regimen should now
be tested in patients with less advanced stages of this disease.
References
MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith
F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C. 5-Fluorouracil, doxorubicin,
and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.
Ann Intern Med 1980; 93:533 - 536.

|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
5 - FU....... 600 mg / M2 IV
days 1,8, 29,36
Doxorubicin....... 30 mg / M2 IV days 1,29
Mitomycin C....... 10 mg / M2 IV day 1
FREQUENCY every 56 days. |
|
|
| |
|
|
| |
Summary |
FAM in
the treatment of advanced gastric carcinoma |
| |
Median Survival |
5.5 months |
| |
Toxicity |
only moderate
bone marrow suppression. |
| |
|
|
|
|